Clinical trials
First Line Therapy clinical trials
Below are recruiting first line therapy clinical trials, each written for real people, not researchers. We’re tracking 450 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07299409RecruitingPhase 2
Study of sacituzumab govitecan for advanced triple-negative breast cancer
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
Vancouver, British ColumbiaAges 18 years+ - NCT06869473RecruitingPhase 2
Cetuximab, chemo, and avelumab for head and neck cancer
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
Cagliari, CAGLIARIAges 18 years+ - NCT07290010RecruitingPhase 2
Iparomlimab plus chemotherapy for advanced esophageal cancer
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with chemotherapy as a first treatment for advanced esophageal squamous cell carcinoma. It aims to see if this combination is safe and effective for people whose cancer cannot be removed by surgery or has spread.
Shijiazhuang, HebeiAges 18 years+ - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07284849RecruitingPhase 3
Testing a new drug combo for advanced colorectal cancer
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
Mobile, AlabamaAges 18 years+ - NCT05653453RecruitingPhase 3
Tumor treatment device plus chemo for locally advanced pancreatic cancer
This trial tests whether a home-wearable tumor-treating device (Tumor Treating Fields) combined with gemcitabine and albumin-bound paclitaxel works better as first treatment for locally advanced pancreatic cancer. It may help by targeting cancer cells while also using standard chemotherapy.
Harbin, HeilongjiangAges 18–75 - NCT05299840Recruiting
Test a device to choose the first chemo for metastatic colon cancer
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
MarseilleAges 18 years+ - NCT07257653RecruitingPhase 2
Cetuximab beta plus fruquintinib with or without immunotherapy for first-line advanced colorectal cancer
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
Hangzhou, ZhejiangAges 10–85 - NCT07244016Recruiting
TCR test to guide immunotherapy and chemo for extensive SCLC
This trial tests whether a blood test (TCR) can help predict how well a combination of the immunotherapy drug tislelizumab and chemotherapy works for people with extensive-stage small cell lung cancer (SCLC) that has not been treated before.
Zhengzhou, HenanAges 18 years+ - NCT07245446RecruitingPhase 2
Ivonescimab for untreated extensive-stage SCLC
This study tests a new immunotherapy drug called ivonescimab for people with extensive-stage small cell lung cancer who have not had treatment before. The goal is to see if it can help shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07247227Recruiting
Sugemalimab plus chemotherapy for advanced lung cancer
This trial tests a new immunotherapy drug (sugemalimab) combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It aims to see if this combination works well in real-world patients.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06502743RecruitingPhase 2
Study of chemotherapy and pembrolizumab with or without nesuparib for endometrial cancer
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Kyeonggi-doAges 19 years+ - NCT07219459RecruitingPhase 2
New drug combo for liver cancer after PD-1/PD-L1 treatment fails
This study tests three drugs (visugromab, nivolumab, lenvatinib) compared to a placebo plus lenvatinib for people with liver cancer (HCC) that cannot be removed or has spread, and who have already been treated with a PD-1/PD-L1 inhibitor without success. The goal is to see if the combination can help shrink tumors or slow the cancer.
Irvine, CaliforniaAges 18–100 - NCT07216703RecruitingPhase 3
Study of sacituzumab tirumotecan plus pembrolizumab for cervical cancer
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
Birmingham, AlabamaAges 18 years+ - NCT07221253RecruitingPhase 3
Study of Rilvegostomig or Durvalumab plus chemo for biliary tract cancer
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
Birmingham, AlabamaAges 18 years+ - NCT06926205RecruitingPhase 2
CHOP chemo plus mosunetuzumab for Richter's syndrome first treatment
This trial tests a new immunotherapy drug (mosunetuzumab) combined with standard chemotherapy (CHOP) as the first treatment for Richter's syndrome, a fast-growing lymphoma that can arise from CLL. The goal is to see if this combination helps control the disease better than standard therapy.
Barcelona, BarcelonaAges 18–79 - NCT07185997RecruitingPhase 3
Study of Firmonertinib for first-line treatment of advanced lung cancer with uncommon EGFR mutations
This trial tests a new pill called firmonertinib against standard EGFR inhibitor pills for people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations. It aims to see if firmonertinib works better in stopping the cancer from growing.
Fullerton, CaliforniaAges 18 years+ - NCT07188103RecruitingPhase 2
Ivonescimab and short radiation for advanced esophageal cancer
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
Hefei, AnhuiAges 18–80 - NCT06945705RecruitingPhase 2
Targeted therapy for EGFR-mutant lung cancer with brain spread
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
ZhengzhouAges 18 years+ - NCT07188896RecruitingPhase 2
Immunotherapy combinations for advanced kidney cancer
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07179484Recruiting
Study of CT041 for advanced stomach or junction cancer after first treatment
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
BeijingAges 18–75 - NCT07178795RecruitingPhase 3
New drug vs standard care for HER2-mutant lung cancer
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07169552RecruitingPhase 2
HC010 for first-line PD-L1 positive advanced lung cancer
This trial tests a new drug called HC010 as a first treatment for people with advanced non-small cell lung cancer that is PD-L1 positive. It aims to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new First Line Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first line therapy?
- Yes. Clin2 currently lists 450 recruiting first line therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first line therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first line therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.